| Literature DB >> 31010028 |
Byeoung-Kyu Choi1,2, Hwa-Sun Lee3, Jong Soon Kang4, Hee Jae Shin5,6.
Abstract
Three new hydroxylated rhamnolipids, dokdolipids A-C (1-3) were obtained from the marine actinomycete Actinoalloteichus hymeniacidonis, which was isolated from a sediment sample collected off the coasts of Dokdo island, Republic of Korea. The structures of the isolated compounds were elucidated on the basis of 1D and 2D NMR and mass spectrometric data analyses. Their absolute configurations were assigned using the modified Mosher's method and specific rotation values, as well as acid hydrolysis, chemical derivatizations and subsequent HPLC analysis to determine the configuration of the sugar moieties. All new compounds were evaluated for their cytotoxicity against six cancer cell lines, HCT-15, NUGC-3, NCI-H23, ACHN, PC-3 and MDA-MB-231. Compounds 1-3 displayed moderate cytotoxicity against all the cell lines tested with IC50 values ranging from 13.7-41.5 µM.Entities:
Keywords: Actinoalloteichus hymeniacidonis; biosurfactants; cytotoxicity; rhamnolipids; rhamnose
Mesh:
Substances:
Year: 2019 PMID: 31010028 PMCID: PMC6521253 DOI: 10.3390/md17040237
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1−3 isolated from Actinoalloteichus hymeniacidonis.
1H and 13C NMR data for 1−3 in CD3OD.
| Position | 1 | 2 | 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| Type |
| Type |
| Type | ||||
| 3′- | |||||||||
| 1 | 98.9 | CH | 4.80, br s | 98.9 | CH | 4.79, br s | 99.0 | CH | 4.79, br s |
| 2 | 71.2 | CH | 3.75, br s | 71.3 | CH | 3.75, br s | 71.5 | CH | 3.75, br s |
| 3 | 70.9 | CH | 3.60, dd (9.6, 3.5) | 70.9 | CH | 3.60, dd (9.6, 3.3) | 71.2 | CH | 3.60, overlap |
| 4 | 72.5 | CH | 3.35, dd (9.6, 9.6) | 72.5 | CH | 3.35, dd (9.6, 9.6) | 72.5 | CH | 3.35, dd (9.6, 9.6) |
| 5 | 68.7 | CH | 3.65, dq (9.6, 6.3) | 68.7 | CH | 3.65, dq (9.6, 6.2) | 68.8 | CH | 3.65, overlap |
| 6 | 16.2 | CH3 | 1.23, d (6.3) | 16.4 | CH3 | 1.23, d (6.2) | 16.5 | CH3 | 1.23, d (6.2) |
| 1′ | 173.9 | C | 174.6 | C | 174.0 | C | |||
| 2′ | 40.0 | CH2 | 2.53, dd (13.7, 7.5) | 40.5 | CH2 | 2.52, dd (14.8, 7.2) | 40.0 | CH2 | 2.52, dd (14.4, 7.6) |
| 2.48, dd (13.7, 5.1) | 2.47, dd (14.8, 5.4) | 2.48, dd (14.4, 5.1) | |||||||
| 3′ | 74.2 | CH | 4.08, m | 74.4 | CH | 4.08, m | 74.2 | CH | 4.08, m |
| 4′ | 33.1 | CH2 | 1.55, m | 33.1 | CH2 | 1.56, m | 33.1 | CH2 | 1.32, 1.57, m |
| 5′ | 24.5 | CH2 | 1.29, m | 24.5 | CH2 | 1.30, m | 24.5 | CH2 | 1.32, 1.58, m |
| 6′–15′ | 24.5–29.4 | CH2 | 1.29–1.45, overlap | 24.5–29.4 | CH2 | 1.29–1.45, overlap | 24.5–29.4 | CH2 | 1.29–1.45, overlap |
| 16′ | 38.8 | CH2 | 1.39, m | 42.9 | CH2 | 2.47, t (7.4) | 36.9 | CH2 | 1.45, 1.53, m |
| 17′ | 67.1 | CH | 3.70, m | 210.8 | C | 70.9 | CH | 3.70, m | |
| 18′ | 22.0 | CH3 | 1.13, d (6.2) | 28.3 | CH3 | 2.12, s | 17.8 | CH3 | 1.12, d (6.0) |
| 2- | |||||||||
| 1′′ | 97.5 | CH | 4.79, br s | ||||||
| 2′′ | 71.4 | CH | 3.72, br s | ||||||
| 3′′ | 71.1 | CH | 3.60, overlap | ||||||
| 4′′ | 72.5 | CH | 3.33, dd (9.6, 9.6) | ||||||
| 5′′ | 68.6 | CH | 3.65, overlap | ||||||
| 6′′ | 16.4 | CH3 | 1.23, d (6.2) | ||||||
The assignments were aided by 1H–1H COSY, ROESY, HSQC, and HMBC NMR spectra.
Figure 2Key COSY and HMBC correlations of 1−3.
Figure 3(A) ROESY correlations in the sugar moiety of 1. (B) Δδ− values in ppm of the MTPA esters of the methylated aglycones of 1–3.
Growth inhibition (GI50, μM) values of 1–3 against human tumor cell lines.
| Cell Lines a | GI50 ± SD (μM) | |||
|---|---|---|---|---|
| 1 | 2 | 3 | ADR b | |
| HCT-15 | 41.5 ± 4.3 | 16.7 ± 0.4 | 26.9 ± 2.0 | 0.173 ± 0.007 |
| NUGC-3 | 30.6 ± 3.6 | 19.3 ± 1.9 | 32.0 ± 4.7 | 0.119 ± 0.009 |
| NCI-H23 | 27.5 ± 3.3 | 13.7 ± 0.7 | 36.9 ± 4.7 | 0.130 ± 0.009 |
| ACHN | 34.2 ± 1.7 | 14.1 ± 0.3 | 29.1 ± 1.0 | 0.163 ± 0.012 |
| PC-3 | 37.8 ± 0.1 | 18.2 ± 3.0 | 33.3 ± 3.3 | 0.145 ± 0.001 |
| MDA-MB-231 | 30.6 ± 0.4 | 40.4 ± 1.3 | 25.5 ± 1.6 | 0.128 ± 0.011 |
a HCT-15: Colon cancer, NUGC-3: Stomach cancer, NCI-H23: Lung cancer, ACHN: Renal cancer, PC-3: Prostate cancer, MDA-MB-231: Breast cancer; GI50 values are the concentration corresponding to 50% growth inhibition. b ADR: Adriamycin as standard. SD: Standard deviation.